Esperion Therapeutics Inc at UBS Global Healthcare Conference Transcript
Okay. Great. Good morning. My name is Carter Gould. I am a senior biotech analyst here at UBS. Welcome to day 1 of the Global Healthcare Conference. I'm pleased to welcome Esperion to the stage. Presenting for the company will be CEO, Tim Mayleben. Just a little bit of perspective. A year ago, almost, we were getting one of the first set of Phase III data from Esperion, and since that time they've made pretty remarkable progress, advancing towards approval, all filed with the FDA now, and I'll let Tim to take it from there, he's going to make some opening comments and then we'll sit down for Q&A.
Perfect. Good morning, everyone. Thanks, Carter, and thanks to UBS for the opportunity to be here with you this morning. As Carter said, it's been an eventful and very productive year. I've got 6 or 8 slides that I'm going to run through with you. And then as Carter said, we're going to move to Q&
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |